LWMI
CPRX

Legacy Wealth Management (Idaho)’s Catalyst Pharmaceutical CPRX Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$991 – 348
2026
Q1 		$991 Sell
40
-64
-62% -$1.52K ﹤0.01% 872
2025
Q4 		$2.43K Buy
104
+86
+478% +$1.92K ﹤0.01% 645
2025
Q3 		$355 Hold
18
– – ﹤0.01% 709
2025
Q2 		$391 Sell
18
-17
-49% -$401 ﹤0.01% 674
2025
Q1 		$849 Hold
35
– – ﹤0.01% 658
2024
Q4 		$802 Buy
35
+17
+94% +$365 ﹤0.01% 616
2024
Q3 		$411 Buy
+18
New +$334 ﹤0.01% 625

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legacy Wealth Management (Idaho)'s CPRX Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 40 shares — an estimated $991 sold.

Legacy Wealth Management (Idaho) first reported a position in CPRX in Q3 2024 and held it in 7 quarters. The position peaked at $2.43K in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 40 Catalyst Pharmaceutical shares in Q2 2026, an estimated $991.
  • Legacy Wealth Management (Idaho) first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s Catalyst Pharmaceutical position peaked at $2.43K in Q4 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.